ALNY - Alnylam Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
ALNY price evolution
ALNY
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $812.69 | $1033.02 | $657.8 | $672.25 |
| Short term investments | $1626.69 | $1373.25 | $1399.71 | $1398.43 |
| Net receivables | $327.79 | $325.44 | $220.63 | $219.43 |
| Inventory | $89.15 | $95.77 | $100.45 | $131.88 |
| Total current assets | $2982.7 | $2985.45 | $2524.05 | $2541.02 |
| Long term investments | $49.39 | $49.39 | $49.39 | $49.39 |
| Property, plant & equipment | $725.79 | $729.08 | $736.27 | $738.08 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $847.18 | $853.62 | $878.35 | $850.92 |
| Total investments | $1676.09 | $1422.64 | $1449.1 | $1447.82 |
| Total assets | $3829.88 | $3839.07 | $3402.4 | $3391.94 |
| Current liabilities | ||||
| Accounts payable | $55.52 | $73.84 | $59.75 | $62.24 |
| Deferred revenue | $290.93 | $273.23 | $248.77 | $227.05 |
| Short long term debt | $41.51 | $41.52 | $42.07 | $43.05 |
| Total current liabilities | $967.79 | $949.78 | $788.64 | $673.39 |
| Long term debt | $1263.88 | $1267.52 | $1272.26 | $1277.29 |
| Total noncurrent liabilities | $3082.74 | $3055.15 | $3021.89 | $2977.79 |
| Total debt | $1305.39 | $1309.04 | $1314.33 | $1320.34 |
| Total liabilities | $4050.52 | $4004.94 | $3810.53 | $3651.18 |
| Shareholders' equity | ||||
| Retained earnings | -$7009.59 | -$6871.72 | -$7019.47 | -$6743.45 |
| Other shareholder equity | -$23.38 | -$32.34 | -$37.08 | -$39.12 |
| Total shareholder equity | -$220.64 | -$165.87 | -$408.13 | -$259.24 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $812.69 | $866.39 | $819.98 | $496.58 |
| Short term investments | $1626.69 | $1326.01 | $1615.59 | $1377.82 |
| Net receivables | $327.79 | $237.96 | $198.57 | $102.41 |
| Inventory | $89.15 | $128.96 | $86.36 | $75.2 |
| Total current assets | $2982.7 | $2692.25 | $2808.58 | $2614.78 |
| Long term investments | $49.39 | $49.39 | $40.89 | $40.73 |
| Property, plant & equipment | $725.79 | $738.63 | $733.63 | $706.51 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $847.18 | $854.11 | $834.73 | $792.28 |
| Total investments | $1676.09 | $1375.4 | $1656.48 | $1418.54 |
| Total assets | $3829.88 | $3546.36 | $3643.3 | $3407.06 |
| Current liabilities | ||||
| Accounts payable | $55.52 | $98.09 | $73.43 | $51.97 |
| Deferred revenue | $290.93 | $235.9 | $301.84 | $352.3 |
| Short long term debt | $41.51 | $41.97 | $40.55 | $36.87 |
| Total current liabilities | $967.79 | $767.91 | $695.71 | $585.27 |
| Long term debt | $1263.88 | $1016.94 | $957.04 | $484.32 |
| Total noncurrent liabilities | $3082.74 | $2936.67 | $2359.39 | $1805.54 |
| Total debt | $1305.39 | $1320.25 | $997.59 | $521.19 |
| Total liabilities | $4050.52 | $3704.58 | $3055.1 | $2390.81 |
| Shareholders' equity | ||||
| Retained earnings | -$7009.59 | -$6569.35 | -$5438.19 | -$4585.37 |
| Other shareholder equity | -$23.38 | -$2.39 | -$33.26 | -$43.62 |
| Total shareholder equity | -$220.64 | -$158.22 | $588.2 | $1016.25 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $439.72 | $750.53 | $318.75 | $319.29 |
| Cost of revenue | $85.86 | $84.31 | $85.37 | $54.87 |
| Gross Profit | $353.86 | $666.22 | $233.38 | $264.42 |
| Operating activities | ||||
| Research & development | $272.14 | $253.18 | $248.53 | $230.57 |
| Selling, general & administrative | $198.12 | $199.18 | $214.69 | $183.66 |
| Total operating expenses | $470.26 | $452.35 | $463.21 | $414.23 |
| Operating income | -$116.4 | $213.87 | -$229.83 | -$149.81 |
| Income from continuing operations | ||||
| EBIT | -$106.35 | $181.63 | -$244.17 | -$143.41 |
| Income tax expense | $0.18 | $2.99 | $1.81 | $1.74 |
| Interest expense | $31.34 | $30.89 | $30.04 | $28.95 |
| Net income | ||||
| Net income | -$137.87 | $147.75 | -$276.02 | -$174.1 |
| Income (for common shares) | -$137.87 | $147.75 | -$276.02 | -$174.1 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1828.29 | $1037.42 | $844.29 | $492.85 |
| Cost of revenue | $310.41 | $168.82 | $140.14 | $78.05 |
| Gross Profit | $1517.89 | $868.6 | $704.14 | $414.8 |
| Operating activities | ||||
| Research & development | $1004.41 | $883.01 | $792.16 | $654.82 |
| Selling, general & administrative | $795.65 | $770.66 | $620.64 | $588.42 |
| Total operating expenses | $1800.06 | $1653.67 | $1412.8 | $1243.24 |
| Operating income | -$282.18 | -$785.07 | -$708.65 | -$828.44 |
| Income from continuing operations | ||||
| EBIT | -$312.3 | -$971.02 | -$709.12 | -$771.1 |
| Income tax expense | $6.72 | $4.16 | $0.68 | $2.68 |
| Interest expense | $121.22 | $155.97 | $143.02 | $84.5 |
| Net income | ||||
| Net income | -$440.24 | -$1131.16 | -$852.82 | -$858.28 |
| Income (for common shares) | -$440.24 | -$1131.16 | -$852.82 | -$858.28 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$137.87 | $147.75 | -$276.02 | -$174.1 |
| Operating activities | ||||
| Depreciation | $23.97 | $23.53 | $23.45 | $26.08 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $41.99 | $63.94 | $75.8 | $39.95 |
| Total cash flows from operations | -$29.8 | $359.41 | -$58.99 | -$166.47 |
| Investing activities | ||||
| Capital expenditures | -$15.31 | -$17.09 | -$15.92 | -$13.89 |
| Investments | -$225.35 | $10.77 | $7.21 | -$62.33 |
| Total cash flows from investing | -$240.66 | -$10.76 | -$8.71 | -$76.22 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $30.89 | $24.8 | $49.39 | $42.37 |
| Net borrowings | ||||
| Total cash flows from financing | $39.23 | $33.14 | $53.39 | $46.37 |
| Effect of exchange rate | $10.9 | -$6.55 | -$0.13 | $2.18 |
| Change in cash and equivalents | -$220.33 | $375.23 | -$14.44 | -$194.15 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$440.24 | -$1131.16 | -$852.82 | -$858.28 |
| Operating activities | ||||
| Depreciation | $97.03 | $85.55 | $89.69 | $74.44 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $221.68 | $230.65 | $165.72 | $139.87 |
| Total cash flows from operations | $104.16 | -$541.27 | -$641.69 | -$614.96 |
| Investing activities | ||||
| Capital expenditures | -$62.21 | -$72.06 | -$76.37 | -$70.36 |
| Investments | -$269.7 | $246.11 | -$192.73 | -$359.86 |
| Total cash flows from investing | -$336.35 | $169.35 | -$273.3 | -$435.52 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $147.46 | $259.36 | $246.27 | $299.98 |
| Net borrowings | $135.39 | $500 | $200 | |
| Total cash flows from financing | $172.13 | $425.75 | $1247.12 | $994.98 |
| Effect of exchange rate | $6.39 | -$7.43 | -$9.02 | $4.92 |
| Change in cash and equivalents | -$53.67 | $46.4 | $323.11 | -$50.58 |
News
Fundamentals
| Market cap | $18.28B |
|---|---|
| Enterprise value | $18.77B |
| Shares outstanding | 125.79M |
| Revenue | $1.83B |
|---|---|
| EBITDA | -$215.26M |
| EBIT | -$312.30M |
| Net Income | -$440.24M |
| Revenue Q/Q | 31.25% |
| Revenue Y/Y | 76.23% |
| P/E ratio | -41.52 |
|---|---|
| EV/Sales | 10.27 |
| EV/EBITDA | -87.21 |
| EV/EBIT | -60.11 |
| P/S ratio | 10.00 |
| P/B ratio | -92.67 |
| Book/Share | -1.57 |
| Cash/Share | 6.46 |
| EPS | -$3.50 |
|---|---|
| ROA | -12.18% |
| ROE | 167.09% |
| Debt/Equity | -18.36 |
|---|---|
| Net debt/EBITDA | -15.04 |
| Current ratio | 3.08 |
| Quick ratio | 2.99 |